PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

CHMP gives positive opinion recommending authorisation to GSK’s CKD drug

Chronic kidney disease affects roughly 700 million patients worldwide.

Global biopharmaceutical company GSK has announced that the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has given its drug treatment for symptomatic anaemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis a positive recommendation for authorisation.

Daprodustat is a hypoxia-inducible factor?prolyl hydroxylase inhibitor (HIF-PHI). Inhibition of oxygen-sensing prolyl hydroxylase enzymes stabilises hypoxia-inducible factors, which can lead to the transcription of erythropoietin and other genes associated with the correction of anaemia. It was approved by the US Food and Drug Administration in February 2023 for the treatment of anaemia due to CKD in adults who have been receiving dialysis for at least four months.

The positive CHMP opinion was made due to data from three phase 3 global trials ? ASCEND-D, ASCEND-ID and ASCEND-DT. The trials assessed the efficacy and safety of daprodustat for the treatment of CKD-associated anaemia compared to standard-of-care erythropoiesis-stimulating agent (ESA) therapy in adult patients: on dialysis, (ASCEND-D, November 2021); on incident dialysis (ASCEND-ID, April 2022); and three-times weekly dosed on dialysis (ASCEND-TD, September 2022).

CKD, a progressive loss of kidney function, affects roughly 700 million patients worldwide, with an estimated one in seven developing anaemia. This results in an increase in morbidity, mortality and reduced quality of life.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026